Article: Ekso’s Q4 pre-announcement ‘bodes well’ for 2020 growth, says H.C. Wainwright

Article - Media

Ekso’s Q4 pre-announcement ‘bodes well’ for 2020 growth, says H.C. Wainwright

TheFly, 10 January 2020

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $1.20 price target on Ekso Bionics, saying the pre-announced “record” fourth quarter “bodes well” for continued growth in 2020.

Read full article.

 

Comment: This appears to be a stellar example of a life-saving vital technology company being destroyed by collusion between a placement agent and naked short sellers.

 

RELATED: